The study of polygenic risk suggests that many small effect size Alzheimer’s disease variants beyond APOE are a predictor of atrophy acceleration in healthy individuals (and perhaps also MCI subjects). The gene discussed is APOE; the disease is early-onset autosomal dominant Alzheimer disease.